Eventide Healthcare Life Fund Investor Sentiment

ETIHX Fund  USD 33.30  0.15  0.45%   
Slightly above 54% of Eventide Healthcare's investor base is interested to short. The analysis of overall sentiment of trading Eventide Healthcare Life mutual fund suggests that many investors are impartial at this time. Eventide Healthcare's investing sentiment can be driven by a variety of factors including economic data, Eventide Healthcare's earnings reports, geopolitical events, and overall market trends.
  
a day ago at thelincolnianonline.com         
Collegium Pharmaceutical, Inc. EVP Sells 67,650.00 in Stock
news
few days ago at seekingalpha.com         
Collegium Pharmaceutical chairman of the board to retire
seekingalpha News
six days ago at thelincolnianonline.com         
Colleen Tupper Sells 10,445 Shares of Collegium Pharmaceutical, Inc. Stock
news
over a week ago at thelincolnianonline.com         
Collegium Pharmaceutical, Inc. CFO Colleen Tupper Sells 1,949 Shares
news
over a week ago at news.google.com         
Collegium Pharmaceutical, Inc. EVP Sells 742,909.50 in Stock - Defense World
Google News at Macroaxis
over two weeks ago at finance.yahoo.com         
Collegium Pharmaceuticals Solid Earnings Are Supported By Other Strong Factors
Yahoo News
over two weeks ago at www.macroaxis.com         
Disposition of 20000 shares by Shirley Kuhlmann of Collegium Pharmaceutical at 28.0264 subject to Ru...
Macroaxis News
over two weeks ago at www.macroaxis.com         
Acquisition by Heffernan Michael Thomas of 4820 shares of Collegium Pharmaceutical subject to Rule 1...
Macroaxis News
over two weeks ago at insidermonkey.com         
Is Collegium Pharmaceutical, Inc. the Best Small Cap Pharma Stocks to Buy Now?
insidermonkey News
over two weeks ago at thelincolnianonline.com         
Collegium Pharmaceutical Posts Quarterly Earnings Results, Beats Estimates By 0.09 EPS
news
over six months ago at seekingalpha.com         
Tectonic, AVROBIO complete merger, announce 130.7M private placement
seekingalpha News
over six months ago at news.google.com         
Gabelli Funds LLC Invests 467000 in AVROBIO, Inc. - Defense World
Google News at Macroaxis
over six months ago at news.google.com         
AVROBIO, Inc. Short Interest Up 11.3 percent in May - MarketBeat
Google News at Macroaxis
over six months ago at investing.com         
Avrobio executive buys shares worth over 970k
Investing News at Macroaxis
over six months ago at investorplace.com         
Discretionary transaction by Leonard Braden Michael of tradable shares of AVROBIO subject to Rule 16...
sbwire news
over six months ago at news.google.com         
AVROBIO Options Chain Prices 2024 - MarketBeat
Google News at Macroaxis
over a year ago at news.google.com         
AVROBIO Posts Quarterly Earnings Results - MarketBeat
Google News at Macroaxis
over a year ago at thelincolnianonline.com         
AVROBIO, Inc. Short Interest Update
news
over a year ago at benzinga.com         
SHAREHOLDER UPDATE Halper Sadeh LLC Investigates AXNX, KAMN, JNPR, AVRO
benzinga news
over a year ago at news.google.com         
AVROBIO INVESTOR ALERT by the Former Attorney General of Louisiana Kahn Swick Foti, LLC Investigates...
Google News at Macroaxis
a minute ago at thelincolnianonline.com         
AbbVie Inc. Shares Sold by Janney Montgomery Scott LLC
news
a minute ago at thelincolnianonline.com         
Silver Oak Securities Incorporated Boosts Holdings in AbbVie Inc.
news
a day ago at thelincolnianonline.com         
AbbVie Shares Down 0.7 percent Should You Sell?
news
2 days ago at thelincolnianonline.com         
HUB Investment Partners LLC Acquires 2,565 Shares of AbbVie Inc.
news
3 days ago at talkmarkets.com         
Master Market Trends Elliott Wave Trading On SP 500, Nasdaq, DAX, FTSE ASX200
news
few days ago at zacks.com         
AbbVie Stock Moves -0.29 percent What You Should Know
zacks News
few days ago at thelincolnianonline.com         
1ST Source Bank Sells 219 Shares of AbbVie Inc.
news
few days ago at thelincolnianonline.com         
Flagship Wealth Advisors LLC Purchases Shares of 4,787 AbbVie Inc.
news
few days ago at finance.yahoo.com         
AbbVie Reports ELAHERE Success in Phase 3 Trials for Platinum-Resistant Ovarian Cancer
Yahoo News
six days ago at thelincolnianonline.com         
AbbVie Inc. Shares Sold by Buckley Wealth Management LLC
news
17 hours ago at thelincolnianonline.com         
Veracyte, Inc. Receives Average Recommendation of Moderate Buy from Brokerages
news
2 days ago at investors.com         
Stocks Showing Improving Market Leadership Veracyte Earns 81 RS Rating
Investors Business Daily at Macroaxis
few days ago at investors.com         
Stocks To Watch Veracyte Sees Relative Strength Rating Rise To 82
Investors Business Daily at Macroaxis
over a week ago at finance.yahoo.com         
Acquisition by Febbo Phillip G. of 24160 shares of Veracyte subject to Rule 16b-3
Yahoo News
over two weeks ago at gurufocus.com         
Insider Sell Phillip Febbo Sells Shares of Veracyte Inc
Gurufocus Stories at Macroaxis
over two weeks ago at gurufocus.com         
Veracyte Inc Shares Down 2.49 percent on Mar 5
Gurufocus Stories at Macroaxis
over two weeks ago at finance.yahoo.com         
Disposition of 1142 shares by Annie McGuire of Veracyte at 33.6922 subject to Rule 16b-3
Yahoo News
over two weeks ago at www.macroaxis.com         
Disposition of 8255 shares by Annie McGuire of Veracyte at 34.76 subject to Rule 16b-3
Macroaxis News
over two weeks ago at gurufocus.com         
Veracyte Inc Shares Up 3.52 percent on Feb 28
Gurufocus Stories at Macroaxis
over three weeks ago at simplywall.st         
Veracyte Full Year 2024 Earnings EPS Misses Expectations
Simply Wall St News at Macroaxis
17 hours ago at thelincolnianonline.com         
Maryland State Retirement Pension System Has 1.65 Million Stock Holdings in Alnylam Pharmaceuticals,...
news
2 days ago at seekingalpha.com         
Alnylam nabs key additional indication for Amvuttra
seekingalpha News
few days ago at finance.yahoo.com         
mRNA Vaccines Market Trends and Competition Analysis 2025-2030 Revenues are Projected to Nearly Doub...
Yahoo News
few days ago at finance.yahoo.com         
RNA Therapeutics Market is expected to generate a revenue of USD 22.37 Billion by 2032, Globally, at...
Yahoo News
over a week ago at finance.yahoo.com         
Alnylam Rallies 62 percent in a Year Can the Stock Maintain This Momentum?
Yahoo News
over a week ago at finance.yahoo.com         
Disposition of 2750 shares by Schulman Amy W of Alnylam Pharmaceuticals at 131.21 subject to Rule 16...
Yahoo News
over a week ago at finance.yahoo.com         
WearOptimo Introduces World-Class Advisory Board to Further Advance Microwearable Sensor Technology ...
Yahoo News
over a week ago at news.google.com         
Disposition of 1173 shares by Greenstreet Yvonne of Alnylam Pharmaceuticals at 243.36 subject to Rul...
Google News at Macroaxis
over two weeks ago at finance.yahoo.com         
Is SPDR SP Biotech ETF a Strong ETF Right Now?
Yahoo News
over two weeks ago at gurufocus.com         
Disposition of tradable shares by Poulton Jeffrey V. of Alnylam Pharmaceuticals at 247.35 subject to...
Gurufocus Stories at Macroaxis
a day ago at kalkinemedia.com         
How Does AnaptysBio Fit Into the Broader Biotech Landscape?
news
2 days ago at finance.yahoo.com         
SGS Achieves ISO 450012018 ANAB Accreditation in North America
Yahoo News
few days ago at news.google.com         
AnaptysBio, Inc. Position Raised by Victory Capital Management Inc. - MarketBeat
Google News at Macroaxis
over a week ago at news.google.com         
Rhumbline Advisers Grows Position in AnaptysBio, Inc. - Defense World
Google News at Macroaxis
over two weeks ago at news.google.com         
Leerink Partnrs Weighs in on AnaptysBio FY2029 Earnings - MarketBeat
Google News at Macroaxis
over two weeks ago at simplywall.st         
AnaptysBio Full Year 2024 Earnings Beats Expectations
Simply Wall St News at Macroaxis
over two weeks ago at finance.yahoo.com         
ANABs Certificate Accreditation Program Issues Transition Plan for Latest Version of ANSIASTM E2659 ...
Yahoo News
over three weeks ago at finance.yahoo.com         
AnaptysBio, Inc. Reports Q4 Loss, Tops Revenue Estimates
Yahoo News
over a month ago at www.macroaxis.com         
Acquisition by Daniel Faga of 107350 shares of AnaptysBio subject to Rule 16b-3
Macroaxis News
over a month ago at zacks.com         
AnaptysBio Surges 30.5 percent Is This an Indication of Further Gains?
zacks News
3 days ago at www.macroaxis.com         
Acquisition by Vittiglio Joseph of 50000 shares of Bluebird Bio subject to Rule 16b-3
Macroaxis News
over a week ago at prnewswire.com         
LINGO RELEASES SPACE-THEMED STEM KITS AS FOUNDER PREPARES FOR HISTORIC ALL-FEMALE BLUE ORIGIN FLIGHT
prnewswire News
over a week ago at finance.yahoo.com         
BMS to acquire longtime cell therapy partner 2seventy bio for 286m
Yahoo News
over two weeks ago at prnewswire.com         
BLUE CROSS BLUE SHIELD OF MASSACHUSETTS AND MASSCHALLENGE ANNOUNCE 2025 HEALTH EQUITY BUSINESS ACCEL...
prnewswire News
over two weeks ago at news.google.com         
bluebird bio stock slides for second day on buyout news - MSN
Google News at Macroaxis
over three weeks ago at zacks.com         
Biotech Stock Roundup BLUE Down on Update, News From GILD, TRDA
zacks News
over three weeks ago at seekingalpha.com         
bluebird bio stock on watch after MA deal
seekingalpha News
over three weeks ago at businesswire.com         
Shareholder Alert Ademi LLP investigates whether bluebird bio, Inc. is obtaining a Fair Price for it...
businesswire News
over a month ago at prnewswire.com         
BLUE CROSS BLUE SHIELD OF MASSACHUSETTS ENHANCES DIABETES SUPPORT FOR MEMBERS
prnewswire News
over a month ago at globenewswire.com         
Blue Point Brewing Announces 5th Annual Shakedown on Main Street Festival
Macroaxis News: globenewswire.com
a day ago at globenewswire.com         
Acquisition by Pfreundschuh Peter P. of 60000 shares of Voyager Therapeutics at 7.6 subject to Rule ...
Macroaxis News: globenewswire.com
over a week ago at www.macroaxis.com         
Acquisition by Sandrock Alfred of 145000 shares of Voyager Therapeutics subject to Rule 16b-3
Macroaxis News
over a week ago at thelincolnianonline.com         
Voyager Therapeutics Earns Overweight Rating from Cantor Fitzgerald
news
over a week ago at finance.yahoo.com         
Voyager Therapeutics Q4 Earnings Snapshot
Yahoo News
over a week ago at news.google.com         
Rhumbline Advisers Increases Stake in Voyager Therapeutics, Inc. - Defense World
Google News at Macroaxis
over two weeks ago at finance.yahoo.com         
New tau candidates, including an RNA therapy from Voyager, drive a multi-pronged Alzheimers approach
Yahoo News
over two weeks ago at globenewswire.com         
Voyager Reports Positive Topline Data for Single Ascending Dose Trial of Anti-Tau Antibody VY7523 an...
Macroaxis News: globenewswire.com
over three weeks ago at globenewswire.com         
VOYAGER ALERT Bragar Eagel Squire, P.C. is Investigating Voyager Therapeutics, Inc. on Behalf of Voy...
Macroaxis News: globenewswire.com
over three weeks ago at news.google.com         
Acquisition by Robin Swartz of 71250 shares of Voyager Therapeutics subject to Rule 16b-3
Google News at Macroaxis
over three weeks ago at businesswire.com         
Disposition of 3894 shares by Robin Swartz of Voyager Therapeutics at 4.25 subject to Rule 16b-3
businesswire News
over three weeks ago at gurufocus.com         
Stonepine Capital Management, LLC Acquires Significant Stake in Edesa Biotech Inc
Gurufocus Stories at Macroaxis
over a month ago at gurufocus.com         
Galapagos NV Earnings Call Highlights Strategic Shifts and Financial Resilience
Gurufocus Stories at Macroaxis
over a month ago at seekingalpha.com         
Galapagos projects 2026 pivotal trials for GLPG5101 following FDA clearance
seekingalpha News
over a month ago at finance.yahoo.com         
Galapagos Loses -21.19 percent in 4 Weeks, Heres Why a Trend Reversal May be Around the Corner
Yahoo News
over a month ago at news.google.com         
Galapagos downgraded by Barclays, PT cut to 22 - Investing.com
Google News at Macroaxis
over two months ago at news.google.com         
Belgium stocks lower at close of trade BEL 20 down 1.58 percent - Investing.com
Google News at Macroaxis
over three months ago at gurufocus.com         
Galapagos NV Stock Surges Amid Strong Industry Performance
Gurufocus Stories at Macroaxis
over three months ago at gurufocus.com         
Stonepine Capital Management, LLC Increases Stake in Verastem Inc
Gurufocus Stories at Macroaxis
over three months ago at gurufocus.com         
Prosight Management, LP Expands Stake in ADC Therapeutics SA
Gurufocus Stories at Macroaxis
over three months ago at insidermonkey.com         
Galapagos NV Q3 2024 Earnings Call Transcript
insidermonkey News
over a year ago at thelincolnianonline.com         
Mirati Therapeutics Now Covered by Analysts at StockNews.com
news
over a year ago at finance.yahoo.com         
Billionaire Joe Lewis Pleads Guilty in Insider Trading Case
Yahoo News
over a year ago at smh.com.au         
Billionaire pleads guilty in insider trading case with a link to an Australian giant
news
over a year ago at streetinsider.com         
Frances Sanofi to buy U.S. drugs project INBRX-101 for about 2.2 billion
Street Insider News
over a year ago at streetinsider.com         
Frances Sanofi to buy U.S. drugs project INBRX-101 for about 2.2 billion
Street Insider News
over a year ago at streetinsider.com         
Frances Sanofi to buy U.S. drugs project INBRX-101 for about 2.2 billion
Street Insider News
over a year ago at streetinsider.com         
Frances Sanofi to buy U.S. drugs project INBRX-101 for about 2.2 billion
Street Insider News
over a year ago at aol.com         
Frances Sanofi to buy U.S. drugs project INBRX-101 for about 2.2 billion
news
over a year ago at seekingalpha.com         
Mirati Therapeutics stock ticks higher amid Nasdaq delisting for sale to Bristol-Myers
seekingalpha News
over a year ago at thelincolnianonline.com         
Brokerages Set Mirati Therapeutics, Inc. PT at 60.00
news
over a year ago at hawaiinewsnow.com         
Purchase by Sumitomo Chemical Co Ltd of 51599200 shares of Myovant Sciences
news
a minute ago at finance.yahoo.com         
Neurocrines Phase II schizophrenia trial fails to meet primary endpoint
Yahoo News
2 days ago at thelincolnianonline.com         
EverSource Wealth Advisors LLC Acquires 241 Shares of Neurocrine Biosciences, Inc.
news
few days ago at insidermonkey.com         
Is Neurocrine Biosciences, Inc. a Best Biotech Stock According to Billionaires?
insidermonkey News
six days ago at thelincolnianonline.com         
Neurocrine Biosciences, Inc. Shares Sold by Securian Asset Management Inc.
news
over a week ago at thelincolnianonline.com         
Brokerages Set Neurocrine Biosciences, Inc. Price Target at 166.90
news
over a week ago at thelincolnianonline.com         
Sound View Wealth Advisors Group LLC Acquires 652 Shares of Neurocrine Biosciences, Inc.
news
over two weeks ago at gurufocus.com         
Vanguard Group Incs Strategic Acquisition of Neurocrine Biosciences Shares
Gurufocus Stories at Macroaxis
over two weeks ago at simplywall.st         
Neurocrine Biosciences, Inc.s Stock Retreats 25 percent But Earnings Havent Escaped The Attention Of...
Simply Wall St News at Macroaxis
over two weeks ago at finance.yahoo.com         
Dopamine Receptor Antagonists Clinical Trial Pipeline Analysis 10 Key Companies Shaping the Future o...
Yahoo News
over two weeks ago at finance.yahoo.com         
Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus
Yahoo News
17 hours ago at simplywall.st         
Nurix Therapeutics, Inc. Shares May Have Slumped 25 percent But Getting In Cheap Is Still Unlikely
Simply Wall St News at Macroaxis
2 days ago at thelincolnianonline.com         
Insider Trading
news
few days ago at finance.yahoo.com         
Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg for the Treatment of Walden...
Yahoo News
over a week ago at gurufocus.com         
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635
Gurufocus Stories at Macroaxis
over a week ago at finance.yahoo.com         
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635
Yahoo News
over a week ago at zacks.com         
Xilio Therapeutics, Inc. Reports Q4 Loss, Lags Revenue Estimates
zacks News
over two weeks ago at news.google.com         
Nurix Therapeutics Shares Down 6 percent on Insider Selling - MarketBeat
Google News at Macroaxis
over two weeks ago at gurufocus.com         
Insider Sell Alert Houte Van Sells Shares of Nurix Therapeutics Inc
Gurufocus Stories at Macroaxis
over two weeks ago at news.google.com         
Oversold Conditions For Nurix Therapeutics - Nasdaq
Google News at Macroaxis
over a month ago at news.google.com         
Sumitomo Mitsui Trust Group Inc. Has 14.87 Million Holdings in Nurix Therapeutics, Inc. - MarketBeat
Google News at Macroaxis
over a year ago at news.google.com         
Global markets live Adobe, Eli Lilly, Nasdaq, Intel, UBS... - Marketscreener.com
Google News at Macroaxis
over a year ago at thelincolnianonline.com         
Boxer Capital LLC Boosts Stock Position in Prometheus Biosciences, Inc.
news
over a year ago at www.macroaxis.com         
Exercise or conversion by Mark McKenna of 122528 shares of Prometheus Biosciences subject to Rule 16...
Macroaxis News
over a year ago at news.google.com         
PROMETHEUS BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana Kahn Swick Foti, L...
Google News at Macroaxis
over a year ago at simplywall.st         
We Think Prometheus Biosciences Can Afford To Drive Business Growth
Simply Wall St News at Macroaxis
over a year ago at zacks.com         
Prometheus Biosciences, Inc. is a Great Momentum Stock Should You Buy?
zacks News
over a year ago at zacks.com         
Prometheus Biosciences, Inc. Reports Q1 Loss, Tops Revenue Estimates
zacks News
over a year ago at news.google.com         
Ieq Capital LLC Sells off 35.3 percent of Holding in Prometheus ... - Best Stocks
Google News at Macroaxis
over a year ago at news.google.com         
Cocrystal Pharma Appoints Pharma Industry Veteran Fred Hassan to its Board of Directors - Marketscre...
Google News at Macroaxis
over a year ago at fool.com         
Why Madrigal Pharmaceuticals Stock Gained 20 percent This Week
fool News
17 hours ago at www.macroaxis.com         
Disposition of 296 shares by Rothfuss Cristin of Sarepta Therapeutics at 101.34 subject to Rule 16b-...
Macroaxis News
2 days ago at thelincolnianonline.com         
Sarepta Therapeutics Shares Gap Down Time to Sell?
news
3 days ago at benzinga.com         
Nvidia, Meta, Sarepta, D-Wave, And Tesla Why These 5 Stocks Are On Investors Radars Today
benzinga news
3 days ago at insidermonkey.com         
Why Sarepta Therapeutics Inc. Crashed On Tuesday?
insidermonkey News
few days ago at thelincolnianonline.com         
Medical Stocks To Follow Today March 18th
news
six days ago at thelincolnianonline.com         
Claude Nicaise Sells 2,491 Shares of Sarepta Therapeutics, Inc. Stock
news
over a week ago at kalkinemedia.com         
How Is Sarepta Therapeutics Strengthening Its Market Position?
news
over a week ago at benzinga.com         
Acquisition by Behrens M Kathleen of 4792 shares of Sarepta Therapeutics at 99.69 subject to Rule 16...
benzinga news
over two weeks ago at zacks.com         
Disposition of 8527 shares by Bilal Arif of Sarepta Therapeutics at 103.7 subject to Rule 16b-3
zacks News
over two weeks ago at finance.yahoo.com         
Insider Trading
Yahoo News
17 hours ago at www.macroaxis.com         
Acquisition by Linda Fitzpatrick of 8750 shares of Sutro Biopharma subject to Rule 16b-3
Macroaxis News
few days ago at finance.yahoo.com         
Sutro Biopharma Full Year 2024 Earnings Revenues Beat Expectations, EPS Lags
Yahoo News
over a week ago at bizjournals.com         
Longtime Peninsula biotech to chop half its jobs, CEO exits
bizjournals News
over a week ago at gurufocus.com         
Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights
Gurufocus Stories at Macroaxis
over a week ago at zacks.com         
Oculis Holding AG Reports Q4 Loss, Misses Revenue Estimates
zacks News
over two weeks ago at www.macroaxis.com         
Disposition of 8750 shares by Edward Albini of Sutro Biopharma subject to Rule 16b-3
Macroaxis News
over two weeks ago at www.macroaxis.com         
Disposition of 11250 shares by Borgman Anne Elizabeth of Sutro Biopharma subject to Rule 16b-3
Macroaxis News
over a month ago at simplywall.st         
Shareholders in Sutro Biopharma have lost 86, as stock drops 18 percent this past week
Simply Wall St News at Macroaxis
over a month ago at finance.yahoo.com         
Were Not Very Worried About Sutro Biopharmas Cash Burn Rate
Yahoo News
over two months ago at simplywall.st         
Great week for Sutro Biopharma, Inc. institutional investors after losing 42 percent over the previo...
Simply Wall St News at Macroaxis
over six months ago at www.macroaxis.com         
Disposition of 8500 shares by Jonas Jeffrey M of Karuna Therapeutics at 128.01 subject to Rule 16b-3
Macroaxis News
over six months ago at bizjournals.com         
PureTechs newest biotech spinout represents a shift from the past
bizjournals News
over a year ago at news.google.com         
Disposition of 17350 shares by Stephen Brannan of Karuna Therapeutics at 187.26 subject to Rule 16b-...
Google News at Macroaxis
over a year ago at simplywall.st         
When Will Karuna Therapeutics, Inc. Turn A Profit?
Simply Wall St News at Macroaxis
over a year ago at news.google.com         
Karuna Therapeutics, Inc. Receives Consensus Recommendation of Hold from Analysts - Defense World
Google News at Macroaxis
over a year ago at finance.yahoo.com         
Bronte Amalthea Fund Incurred Loss in Karuna Therapeutics Short Position
Yahoo News
over a year ago at www.macroaxis.com         
Acquisition by Steven Paul of 47378 shares of Karuna Therapeutics at 315.18 subject to Rule 16b-3
Macroaxis News
over a year ago at seekingalpha.com         
Karuna Therapeutics stock drops on no apparent news amid deal with Bristol-Myers Squibb
seekingalpha News
over a year ago at thelincolnianonline.com         
Algert Global LLC Has 3.12 Million Stock Holdings in Karuna Therapeutics, Inc.
news
over a year ago at zacks.com         
Acquisition by Steven Paul of 27510 shares of Karuna Therapeutics at 7.27 subject to Rule 16b-3
zacks News
17 hours ago at thelincolnianonline.com         
Acerus Pharmaceuticals vs. Allakos Head-To-Head Survey
news
over a week ago at gurufocus.com         
Allakos Provides Business Update and Reports Fourth Quarter 2024 Financial Results
Gurufocus Stories at Macroaxis
over two weeks ago at news.google.com         
The Curious Case of Allakos - substack.com
Google News at Macroaxis
over a month ago at news.google.com         
TANG CAPITAL MANAGEMENT LLC Acquires Significant Stake in Allakos Inc - GuruFocus.com
Google News at Macroaxis
over a month ago at finance.yahoo.com         
Allakos Announces Topline Results from its Phase 1 Trial of AK006 in Patients with Chronic Spontaneo...
Yahoo News
over a month ago at news.google.com         
Allakos Shares Plummet to All-Time Low After Lead Candidate Failure - MarketWatch
Google News at Macroaxis
over two months ago at news.google.com         
Allakos Inc. Short Interest Update - MarketBeat
Google News at Macroaxis
over three months ago at thelincolnianonline.com         
Disposition of 13138 shares by Radford Harlan Baird of Allakos at 1.1 subject to Rule 16b-3
news
over three months ago at news.google.com         
Allakos Reports Q3 2024 Results and Research Progress - TipRanks
Google News at Macroaxis
over three months ago at news.google.com         
FMR LLCs Strategic Acquisition of Allakos Inc Shares - GuruFocus.com
Google News at Macroaxis
a day ago at thelincolnianonline.com         
iA Global Asset Management Inc. Purchases 270 Shares of argenx SE
news
few days ago at zacks.com         
Argenx Surges 4.1 percent Is This an Indication of Further Gains?
zacks News
over a week ago at finance.yahoo.com         
Artisan Small Cap Fund Sold argenx SE as it Exceeded Small-Cap Mandate
Yahoo News
over two weeks ago at thelincolnianonline.com         
Wedbush Comments on argenxs Q2 Earnings
news
over two weeks ago at thelincolnianonline.com         
Robert W. Baird Forecasts Strong Price Appreciation for argenx Stock
news
over two weeks ago at insidermonkey.com         
argenx SE Q4 2024 Earnings Call Transcript
insidermonkey News
over three weeks ago at gurufocus.com         
argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update
Gurufocus Stories at Macroaxis
over three weeks ago at zacks.com         
Jazz Stock Gains as Q4 Earnings Sales Surpass Expectations
zacks News
over three weeks ago at gurufocus.com         
argenx SE to Present at TD Cowen 45th Annual Healthcare Conference
Gurufocus Stories at Macroaxis
over three weeks ago at zacks.com         
SpringWorks Q4 Loss Wider Than Expected, Revenues Beat Estimates
zacks News
a day ago at news.google.com         
Biotech designed to commercialize Ascendis endocrinology drugs in China files 86M IPO - FiercePharma
Google News at Macroaxis
few days ago at finance.yahoo.com         
Ascendis Pharma Soars 10.4 percent Is Further Upside Left in the Stock?
Yahoo News
over a week ago at news.google.com         
Ascendis Pharma Grants Employee Warrants to Strengthen Retention - TipRanks
Google News at Macroaxis
over two weeks ago at gurufocus.com         
Avoro Capital Advisors LLC Increases Stake in Aadi Bioscience Inc
Gurufocus Stories at Macroaxis
over three weeks ago at thelincolnianonline.com         
Ascendis Pharma AS Shares Sold by Handelsbanken Fonder AB
news
over three weeks ago at gurufocus.com         
Ascendis Pharma to Participate in theTD Cowen 45th Annual Healt
Gurufocus Stories at Macroaxis
over a month ago at thelincolnianonline.com         
Q1 EPS Forecast for Ascendis Pharma AS Decreased by Analyst
news
over a month ago at finance.yahoo.com         
High Growth Tech Stocks And 2 More High Potential Picks
Yahoo News
over a month ago at finance.yahoo.com         
Ascendis Pharma AS Just Reported Annual Earnings Have Analysts Changed Their Mind On The Stock?
Yahoo News
over a month ago at gurufocus.com         
JANUS HENDERSON GROUP PLC Expands Stake in Ascendis Pharma AS
Gurufocus Stories at Macroaxis
few days ago at kalkinemedia.com         
How Is Biohaven Ltd. Supporting Its Clinical Trials?
news
over a week ago at news.google.com         
Biohaven Ltd. Shares Bought by Bank of New York Mellon Corp - Defense World
Google News at Macroaxis
over a week ago at finance.yahoo.com         
Biohaven Ltd. Among Stocks with Heavy Insider Buying in 2025
Yahoo News
over two weeks ago at kalkinemedia.com         
How Biohaven Ltd. Is Advancing Treatments for Complex Disorders
news
over two weeks ago at gurufocus.com         
INVESTOR ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN
Gurufocus Stories at Macroaxis
over two weeks ago at thelincolnianonline.com         
Biohaven Ltd. Director Purchases 996,369.00 in Stock
news
over two weeks ago at gurufocus.com         
Beyond the Balance Sheet What SWOT Reveals About Biohaven Ltd
Gurufocus Stories at Macroaxis
over two weeks ago at thelincolnianonline.com         
Acquisition by John Childs of 3400 shares of Biohaven Pharmaceutical at 30.7261 subject to Rule 16b-...
news
over two weeks ago at gurufocus.com         
Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial ...
Gurufocus Stories at Macroaxis
over two weeks ago at gurufocus.com         
Biohaven Ltd Announces FDA Priority Review and Financial Results
Gurufocus Stories at Macroaxis
a minute ago at benzinga.com         
IonQ, HE Equipment Services And ImmunityBio Are Among Top Mid Cap Gainers Last Week Are The Others I...
benzinga news
3 days ago at kalkinemedia.com         
Is Blueprint Medicines Gaining Momentum in the Biotechnology Sector?
news
over a week ago at news.google.com         
Disposition of 1800 shares by Albers Jeffrey W. of Blueprint Medicines at 88.37 subject to Rule 16b-...
Google News at Macroaxis
over a week ago at news.google.com         
Blueprint Medicines Co. Stock Holdings Lifted by Bank of New York Mellon Corp - Defense World
Google News at Macroaxis
over two weeks ago at simplywall.st         
Is Blueprint Medicines A Risky Investment?
Simply Wall St News at Macroaxis
over two weeks ago at www.macroaxis.com         
Disposition of 2541 shares by Hewes L. Becker of Blueprint Medicines at 87.98 subject to Rule 16b-3
Macroaxis News
over two weeks ago at thelincolnianonline.com         
Disposition of 1075 shares by Ariel Hurley of Blueprint Medicines at 95.16 subject to Rule 16b-3
news
over two weeks ago at www.macroaxis.com         
Acquisition by Haviland Kate of 70400 shares of Blueprint Medicines at 96.57 subject to Rule 16b-3
Macroaxis News
over two weeks ago at finance.yahoo.com         
Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI WAO J...
Yahoo News
over three weeks ago at finance.yahoo.com         
Blueprint Medicines Corporation Among the Oversold Biotech Stocks to Buy Now
Yahoo News
2 days ago at thefly.com         
Celldex initiated with bullish view at Morgan Stanley, heres why CLDX
news
over a week ago at news.google.com         
Trading Advice - Stock Traders Daily
Google News at Macroaxis
over two weeks ago at gurufocus.com         
Celldex Therapeutics Inc Announces Participation in Upcoming Healthcare Conferences
Gurufocus Stories at Macroaxis
over two weeks ago at gurufocus.com         
Celldex Therapeutics Inc Announces Promising Preclinical Data for CDX-622
Gurufocus Stories at Macroaxis
over two weeks ago at finance.yahoo.com         
Celldex Therapeutics Full Year 2024 Earnings Revenues Beat Expectations, EPS In Line
Yahoo News
over two weeks ago at gurufocus.com         
Celldex Therapeutics Inc Reports Positive Phase 2 Results for Barzolvolimab in Chronic ...
Gurufocus Stories at Macroaxis
over two weeks ago at thelincolnianonline.com         
Celldex Therapeutics Receives Buy Rating from HC Wainwright
news
over three weeks ago at gurufocus.com         
Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
Gurufocus Stories at Macroaxis
over three weeks ago at finance.yahoo.com         
Celldex Therapeutics Reports Q4 Loss, Lags Revenue Estimates
Yahoo News
over a month ago at gurufocus.com         
Disposition of 27580 shares by Richard Wright of Celldex Therapeutics at 33.5264 subject to Rule 16b...
Gurufocus Stories at Macroaxis
a day ago at thelincolnianonline.com         
iA Global Asset Management Inc. Buys 3,110 Shares of Exact Sciences Co.
news
2 days ago at finance.yahoo.com         
Should You Invest in Exact Sciences Corp.?
Yahoo News
few days ago at thelincolnianonline.com         
Daiwa Securities Group Inc. Raises Stock Holdings in Exact Sciences Co.
news
over a week ago at thelincolnianonline.com         
Exact Sciences Now Covered by Analysts at Royal Bank of Canada
news
over a week ago at kalkinemedia.com         
How Is Exact Sciences Strengthening Its Market Position?
news
over two weeks ago at finance.yahoo.com         
Disposition of 3780 shares by Sarah Condella of EXACT Sciences subject to Rule 16b-3
Yahoo News
over two weeks ago at insidermonkey.com         
Exact Sciences Corporation Among the Cash-Rich Mid Cap Stocks to Buy Now
insidermonkey News
over two weeks ago at thelincolnianonline.com         
Generali Investments Towarzystwo Funduszy Inwestycyjnych Grows Position in Exact Sciences Co.
news
over three weeks ago at thelincolnianonline.com         
Crestwood Advisors Group LLC Grows Stock Position in Exact Sciences Co.
news
over three weeks ago at gurufocus.com         
Exact Sciences Corp Announces Participation in Upcoming Investor Conferences
Gurufocus Stories at Macroaxis
a minute ago at finance.yahoo.com         
Heres What Key Metrics Tell Us About Vertex Q4 Earnings
Yahoo News
a day ago at zacks.com         
Vertex Pharmaceuticals Stock Falls Amid Market Uptick What Investors Need to Know
zacks News
2 days ago at thelincolnianonline.com         
Vertex Pharmaceuticals Incorporated Shares Bought by Royal London Asset Management Ltd.
news
3 days ago at zacks.com         
Vertex Pharmaceuticals Rises But Trails Market What Investors Should Know
zacks News
few days ago at finance.yahoo.com         
NVIDIA, Alphabet and Google Collaborate on the Future of Agentic and Physical AI
Yahoo News
few days ago at statnews.com         
Genetics expert is first NIH director to leave under Trump
news
few days ago at seekingalpha.com         
Google expands Reddit partnership to include use of Vertex AI - report
seekingalpha News
few days ago at channelnewsasia.com         
UK must have global ambition in AI, DeepMinds Hassabis says
news
over a week ago at finance.yahoo.com         
Why Is Alkermes Down 6.6 percent Since Last Earnings Report?
Yahoo News
over a week ago at zacks.com         
Disposition of 3231 shares by Altshuler David of Vertex Pharmaceuticals at 510.0 subject to Rule 16b...
zacks News
a day ago at news.google.com         
Technical Pivots with Risk Controls - Stock Traders Daily
Google News at Macroaxis
over a week ago at www.macroaxis.com         
Acquisition by Benjamin Palleiko of 30195 shares of Kalvista Pharmaceuticals subject to Rule 16b-3
Macroaxis News
over a week ago at news.google.com         
KALVISTA PHARMACEUTICALS Earnings Results KALV Reports Quarterly Earnings - Nasdaq
Google News at Macroaxis
over two weeks ago at www.macroaxis.com         
Disposition of 6669 shares by Benjamin Palleiko of Kalvista Pharmaceuticals at 11.97 subject to Rule...
Macroaxis News
over two weeks ago at thelincolnianonline.com         
Brokerages Set KalVista Pharmaceuticals, Inc. PT at 23.80
news
over two weeks ago at finance.yahoo.com         
KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Ast...
Yahoo News
over three weeks ago at thelincolnianonline.com         
KalVista Pharmaceuticals, Inc. Insider Paul K. Audhya Sells 2,394 Shares of Stock
news
over three weeks ago at thelincolnianonline.com         
KalVista Pharmaceuticals, Inc. CEO Sells 50,121.28 in Stock
news
over three weeks ago at businesswire.com         
KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma...
businesswire News
over three weeks ago at businesswire.com         
Acquisition by Brian Piekos of 80000 shares of Kalvista Pharmaceuticals subject to Rule 16b-3
businesswire News
2 days ago at thelincolnianonline.com         
Twin Tree Management LP Takes Position in uniQure
news
few days ago at thelincolnianonline.com         
Disposition of 10438 shares by Christian Klemt of Uniqure NV at 10.29 subject to Rule 16b-3
news
over a week ago at www.macroaxis.com         
Disposition of 6717 shares by Matthew Kapusta of Uniqure NV at 11.32 subject to Rule 16b-3
Macroaxis News
over two weeks ago at thelincolnianonline.com         
Acquisition by Abi-saab Walid of 66000 shares of Uniqure NV at 10.9 subject to Rule 16b-3
news
over two weeks ago at www.macroaxis.com         
Disposition of 7076 shares by Potts Jeannette of Uniqure NV at 10.29 subject to Rule 16b-3
Macroaxis News
over two weeks ago at simplywall.st         
Dont Ignore The Insider Selling In uniQure
Simply Wall St News at Macroaxis
over two weeks ago at thelincolnianonline.com         
uniQure Price Target Lowered to 30.00 at Wells Fargo Company
news
over three weeks ago at seekingalpha.com         
uniQure GAAP EPS of -4.92 misses by 0.97, revenue of 27.1M misses by 12.3M
seekingalpha News
over three weeks ago at www.macroaxis.com         
Acquisition by Christian Klemt of 5712 shares of Uniqure NV subject to Rule 16b-3
Macroaxis News
over three weeks ago at thelincolnianonline.com         
Acquisition by Jacques Rachelle Suzanne of 8080 shares of Uniqure NV subject to Rule 16b-3
news
17 hours ago at www.macroaxis.com         
Insider Trading
Macroaxis News
few days ago at globenewswire.com         
Acquisition by Barry Greene of 66500 shares of Sage Therapeutic at 45.28 subject to Rule 16b-3
Macroaxis News: globenewswire.com
over a week ago at zacks.com         
Sage Therapeutics Up 7.4 percent Since Last Earnings Report Can It Continue?
zacks News
over two weeks ago at bizjournals.com         
Sages medical chief is latest leader to leave biotech
bizjournals News
over two weeks ago at finance.yahoo.com         
Sage Therapeutics Announces RD Leadership Transition
Yahoo News
over two weeks ago at finance.yahoo.com         
Key Themes, Strategic Moves, and Market Dynamics from JP Morgans 43rd Annual Healthcare Conference, ...
Yahoo News
over three weeks ago at thelincolnianonline.com         
Sage Therapeutics and Phibro Animal Health Head-To-Head Contrast
news
over a month ago at gurufocus.com         
BB Biotech AG Reduces Stake in Agios Pharmaceuticals Inc.
Gurufocus Stories at Macroaxis
over a month ago at insidermonkey.com         
Sage Therapeutics, Inc. Q4 2024 Earnings Call Transcript
insidermonkey News
over a month ago at finance.yahoo.com         
Less Manual Work, More Financial Control Sage Intacct Further Advances AI for Finance Teams
Yahoo News
Far too much social signal, news, headlines, and media speculation about Eventide Healthcare that are available to investors today. That information is available publicly through Eventide media outlets and privately through word of mouth or via Eventide internal channels. However, regardless of the origin, that massive amount of Eventide data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Eventide Healthcare news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Eventide Healthcare relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Eventide Healthcare's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Eventide Healthcare alpha.

Other Information on Investing in Eventide Mutual Fund

Eventide Healthcare financial ratios help investors to determine whether Eventide Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Eventide with respect to the benefits of owning Eventide Healthcare security.
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format